New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
about
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.The role of automated cytometry in the new era of cancer immunotherapyDrug response to PD-1/PD-L1 blockade: based on biomarkers
P2860
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
@en
type
label
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
@en
prefLabel
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
@en
P2093
P2860
P356
P1476
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
@en
P2093
Isabel R Preeshagul
Kevin M Sullivan
Nagashree Seetharamu
P2860
P356
10.2147/LCTT.S113177
P577
2017-07-13T00:00:00Z